Phase II Trial of Phillips MRI-Guided High Intensity Focused Ultrasound (Sonalleve) and Lyso-thermosensitive Liposomal Doxorubicin (ThermoDox) for Palliation of Painful Bone Metastases
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Rate of complete pain response
12 months
No
Nicholas Borys, M.D.
Study Director
Celsion
United States: Food and Drug Administration
106-10-201
NCT01640847
Name | Location |
---|